PTX.AX
Price:
$0.048
Market Cap:
$38.66M
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and chang...[Read more]
Industry
Biotechnology
IPO Date
1999-01-03
Stock Exchange
ASX
Ticker
PTX.AX
According to Prescient Therapeutics Limited’s latest financial reports and current stock price. The company's current PE Ratio is -4.80. This represents a change of 13.35% compared to the average of -4.23 of the last 4 quarters.
The mean historical PE Ratio of Prescient Therapeutics Limited over the last ten years is -9.59. The current -4.80 PE Ratio has changed 4.90% with respect to the historical average. Over the past ten years (40 quarters), PTX.AX's PE Ratio was at its highest in in the March 2013 quarter at 1.19. The PE Ratio was at its lowest in in the June 2021 quarter at -16.71.
Average
-9.59
Median
-5.34
Minimum
-36.13
Maximum
-1.50
Discovering the peaks and valleys of Prescient Therapeutics Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 463.60%
Maximum Annual PE Ratio = -1.50
Minimum Annual Increase = -72.35%
Minimum Annual PE Ratio = -36.13
Year | PE Ratio | Change |
---|---|---|
2024 | -3.91 | -53.52% |
2023 | -8.41 | -57.12% |
2022 | -19.62 | -45.69% |
2021 | -36.13 | 463.60% |
2020 | -6.41 | 155.23% |
2019 | -2.51 | -72.35% |
2018 | -9.08 | 112.45% |
2017 | -4.28 | 5.02% |
2016 | -4.07 | 172.34% |
2015 | -1.50 | -34.78% |
The current PE Ratio of Prescient Therapeutics Limited (PTX.AX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-10.65
5-year avg
-14.90
10-year avg
-9.59
Prescient Therapeutics Limited’s PE Ratio is less than Imugene Limited (-2.09), less than Actinogen Medical Limited (-4.38), less than Patrys Limited (-1.74), less than Antisense Therapeutics Limited (0), greater than Immutep Limited (-7.02),
Company | PE Ratio | Market cap |
---|---|---|
-2.09 | $319.85M | |
-4.38 | $78.32M | |
-1.74 | $6.17M | |
0 | $52.29M | |
-7.02 | $473.07M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prescient Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Prescient Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Prescient Therapeutics Limited's PE Ratio?
How is the PE Ratio calculated for Prescient Therapeutics Limited (PTX.AX)?
What is the highest PE Ratio for Prescient Therapeutics Limited (PTX.AX)?
What is the 3-year average PE Ratio for Prescient Therapeutics Limited (PTX.AX)?
What is the 5-year average PE Ratio for Prescient Therapeutics Limited (PTX.AX)?
How does the current PE Ratio for Prescient Therapeutics Limited (PTX.AX) compare to its historical average?